דף הבית

Lyfebulb Partners יחד עם UnitedHealth יתמכו בחידושים מוכווני חולים לאנשים עם מחלות מעי דלקתיות

פרסום המאמר באתרך

באפשרותך לפרסם את המאמר הזה באתרך בכפוף לתנאי השימוש .בפרסום המאמר עליך להקפיד על הכללים הבאים: יש לפרסם את כותרת המאמר, תוכנו, וכן פרטים אודות כותב המאמר. כמו כן יש לכלול קישור לאתר מאמרים עסקיים ומקצועיים (http://www.portal-asakim.com).

בחזרה למאמר

כותרת המאמר:


תקציר המאמר:
Lyfebulb Partners with UnitedHealth Group to Support Patient-Driven Innovations for People with Inflammatory Bowel Disease

מילות מפתח:


קישור ישיר למאמר:


גירסת HTML:
<html> <head> <title>Lyfebulb Partners יחד עם UnitedHealth יתמכו בחידושים מוכווני חולים לאנשים עם מחלות מעי דלקתיות</title> <meta name="description" content="Lyfebulb Partners with UnitedHealth Group to Support Patient-Driven Innovations for People with Inflammatory Bowel Disease"> <meta name="keywords" content="נוי תקשורת,GLOBE NEWSWIRE,"> <meta name="expires" CONTENT="never"> <meta name="language" CONTENT="hebrew"> <meta name="distribution" CONTENT="Global"> <meta name="robots" content="index, follow"> <meta http-equiv="Content-Type" content="text/html; charset=windows-1255"> </title> <body dir="rtl"> <h1>Lyfebulb Partners יחד עם UnitedHealth יתמכו בחידושים מוכווני חולים לאנשים עם מחלות מעי דלקתיות</h1><br/> <br/><strong>נכתב על ידי: <a title="Lyfebulb Partners יחד עם UnitedHealth יתמכו בחידושים מוכווני חולים לאנשים עם מחלות מעי דלקתיות" href="http://www.portal-asakim.com/Authors//Author576.aspx ">חיים נוי</a></strong><br/> <br/> Lyfebulb Partners יחד עם UnitedHealth יתמכו בחידושים מוכווני חולים לאנשים עם מחלות מעי דלקתיות Lyfebulb Partners with UnitedHealth Group to Support Patient-Driven Innovations for People with Inflammatory Bowel Disease <p>NEW YORK, Jan. 17, 2018 (GLOBE NEWSWIRE):</p> <p>Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients, industry and investors to support user-driven innovation, is partnering with UnitedHealth Group (NYSE:UNH) to launch an innovation challenge featuring new businesses and products aimed at treating inflammatory bowel disease (IBD).</p> <p>According to the Centers of Disease Control and Prevention, up to 1.3 million people in the United States are affected by IBD, which includes Crohn's disease (CD) and ulcerative colitis (UC). Lyfebulb and UnitedHealth Group will help raise awareness for the conditions and stimulate user-driven innovation. By linking entrepreneurs with representatives from UnitedHealth Group and Lyfebulb, the partnership will spotlight the entrepreneurs' efforts and ideas, and provide professional discussion, direction and inspiration.</p> <p>The innovation challenge, to take place in the spring and summer of 2018, will be open to entrepreneurs living with IBD, or who have family members living with IBD, who have founded a company to develop an innovative idea for better management of IBD using pharmaceuticals, biotechnology, medical devices or consumer products. Eligibility criteria and official rules will be announced by Lyfebulb in April. UnitedHealth Group will host an innovation event in July for 10 finalists. A panel of judges will award cash prizes to three winners, to be used for their company's further development of the winning innovations.</p> <p>"Patients living with chronic disease and caregivers caring for someone with chronic disease understand the many challenges they face and are often in the best position to offer tangible solutions," said Deneen Vojta, M.D., executive vice president, Research & Development, UnitedHealth Group. "UnitedHealth Group's partnership with Lyfebulb will help place the patient at the center of early-stage innovation, thus providing us a unique opportunity to learn from and be inspired by patient-entrepreneurs."</p> <p>"This partnership with UnitedHealth Group in IBD means a tremendous amount to Lyfebulb in our efforts to enhance patient-driven innovation," said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb. "Continuing to build on the concept of patient entrepreneurs and partnering with leaders across health care are key components to fulfilling our mission to improve the quality of life of people living with chronic disease."</p> <p><strong>Press Contact for Lyfebulb: </strong></p> <p>Karin Hehenberger, MD, PhD, CEO Lyfebulb, phone: 917-575-0210 email: karin@lyfebulb.com</p> <p><strong>About Lyfebulb</strong></p> <p>Lyfebulb is a chronic disease focused, patient empowerment platform that connects patients, Industry (manufacturers and payers) and investors to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in Diabetes, the company has expanded disease states covered into Cancer and IBD.</p> <p>See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.</p> <p><strong>About UnitedHealth Group</strong></p> <p>UnitedHealth Group (NYSE:UNH) is a diversified health and well-being company dedicated to helping people live healthier lives and helping make the health system work better for everyone. UnitedHealth Group offers a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services. For more information, visit UnitedHealth Group at www.unitedhealthgroup.com or follow @UnitedHealthGrp on Twitter.</p> <p><strong>Press Contact for UnitedHealth Group:</strong><strong></strong></p> <p>Jim Merwin, Senior Director, ERD, phone: 952-936-6070, to email: james_merwin@uhg.com</p> <p>*** <strong>הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית </strong><strong>GLOBE NEWSWIRE</strong><strong></strong></p> <br/><br/> <strong><u>פרטים אודות כותב המאמר</u></strong> <br/> <p><strong>חיים נוי, עיתונאי, עורך ראשי של סוכנות החדשות הבינ"ל IPA, לשעבר עורך ראשי של סוכנות הידיעות עתים, חבר תא מבקרי התיאטרון באגודת העיתונאים</strong></p> <br/><a href="http://www.portal-asakim.com"> מקור המאמר: אתר מאמרים עסקיים ומקצועיים</a>

גירסת טקסט:
Lyfebulb Partners יחד עם UnitedHealth יתמכו בחידושים מוכווני חולים לאנשים עם מחלות מעי דלקתיות Lyfebulb Partners יחד עם UnitedHealth יתמכו בחידושים מוכווני חולים לאנשים עם מחלות מעי דלקתיות Lyfebulb Partners with UnitedHealth Group to Support Patient-Driven Innovations for People with Inflammatory Bowel Disease NEW YORK, Jan. 17, 2018 (GLOBE NEWSWIRE): Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients, industry and investors to support user-driven innovation, is partnering with UnitedHealth Group (NYSE:UNH) to launch an innovation challenge featuring new businesses and products aimed at treating inflammatory bowel disease (IBD). According to the Centers of Disease Control and Prevention, up to 1.3 million people in the United States are affected by IBD, which includes Crohn's disease (CD) and ulcerative colitis (UC). Lyfebulb and UnitedHealth Group will help raise awareness for the conditions and stimulate user-driven innovation. By linking entrepreneurs with representatives from UnitedHealth Group and Lyfebulb, the partnership will spotlight the entrepreneurs' efforts and ideas, and provide professional discussion, direction and inspiration. The innovation challenge, to take place in the spring and summer of 2018, will be open to entrepreneurs living with IBD, or who have family members living with IBD, who have founded a company to develop an innovative idea for better management of IBD using pharmaceuticals, biotechnology, medical devices or consumer products. Eligibility criteria and official rules will be announced by Lyfebulb in April. UnitedHealth Group will host an innovation event in July for 10 finalists. A panel of judges will award cash prizes to three winners, to be used for their company's further development of the winning innovations. "Patients living with chronic disease and caregivers caring for someone with chronic disease understand the many challenges they face and are often in the best position to offer tangible solutions," said Deneen Vojta, M.D., executive vice president, Research & Development, UnitedHealth Group. "UnitedHealth Group's partnership with Lyfebulb will help place the patient at the center of early-stage innovation, thus providing us a unique opportunity to learn from and be inspired by patient-entrepreneurs." "This partnership with UnitedHealth Group in IBD means a tremendous amount to Lyfebulb in our efforts to enhance patient-driven innovation," said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb. "Continuing to build on the concept of patient entrepreneurs and partnering with leaders across health care are key components to fulfilling our mission to improve the quality of life of people living with chronic disease." Press Contact for Lyfebulb: Karin Hehenberger, MD, PhD, CEO Lyfebulb, phone: 917-575-0210 email: karin@lyfebulb.com About Lyfebulb Lyfebulb is a chronic disease focused, patient empowerment platform that connects patients, Industry (manufacturers and payers) and investors to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in Diabetes, the company has expanded disease states covered into Cancer and IBD. See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn. About UnitedHealth Group UnitedHealth Group (NYSE:UNH) is a diversified health and well-being company dedicated to helping people live healthier lives and helping make the health system work better for everyone. UnitedHealth Group offers a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services. For more information, visit UnitedHealth Group at www.unitedhealthgroup.com or follow @UnitedHealthGrp on Twitter. Press Contact for UnitedHealth Group: Jim Merwin, Senior Director, ERD, phone: 952-936-6070, to email: james_merwin@uhg.com *** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית GLOBE NEWSWIRE נכתב על ידי חיים נוי, עיתונאי, עורך ראשי של סוכנות החדשות הבינ"ל IPA, לשעבר עורך ראשי של סוכנות הידיעות עתים, חבר תא מבקרי התיאטרון באגודת העיתונאים מקור המאמר:אתר מאמרים עסקיים ומקצועיים http://www.portal-asakim.com
בחזרה למאמר

לכותבי מאמרים

התחבר הרשמה למערכת שחזור סיסמה

מאמרים בקטגוריות
אימון אישי
אינטרנט והחיים ברשת
בידור ופנאי
ביטוח
בית משפחה וזוגיות
בניין ואחזקה
הודעות לעיתונות
חברה, פוליטיקה ומדינה
חוק ומשפט
חינוך ולימודים
מדעי החברה
מדעי הטבע
מדעי הרוח
מחשבים וטכנולוגיה
מיסים
מתכונים ואוכל
נשים
ספורט וכושר גופני
עבודה וקריירה
עיצוב ואדריכלות
עסקים
פיננסים וכספים
קניות וצרכנות
רוחניות
רפואה ובריאות
תחבורה ורכב
תיירות ונופש

שיווק באינטרנט על ידי WSI